Tevogen Bio Reports $5.7M Net Loss in Q3 2025, Total Assets Rise to $4.5M

Tevogen Bio Holdings Inc. reported a net loss of $5.7 million for the third quarter of 2025, a slight decrease from the $5.9 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company experienced a net loss of $21.6 million, significantly higher than the $4.3 million loss reported for the same period in the previous year. The increase in losses for the nine-month period was primarily attributed to non-cash stock-based compensation expenses, which totaled $13.8 million, and personnel costs. The company has not yet generated any revenue, continuing its trend since inception.

In terms of financial position, Tevogen's total assets increased to $4.5 million as of September 30, 2025, compared to $3.5 million at the end of 2024. The increase was driven by a rise in cash and right-of-use assets, although total liabilities also grew to $12.3 million from $10.1 million, largely due to an increase in accounts payable and a loan agreement. The company’s accumulated deficit reached $135 million, reflecting its ongoing investment in research and development, particularly in its precision T cell therapies.

Operationally, Tevogen has made strides in its clinical development, completing a Phase 1 proof-of-concept trial for its lead product, TVGN 489, aimed at treating high-risk COVID-19 patients. The company is also advancing its Tevogen.AI initiative, which seeks to leverage artificial intelligence to enhance drug development processes. As of September 30, 2025, Tevogen had 197.4 million shares of common stock outstanding, reflecting an increase from the previous year, and it continues to explore various funding strategies to support its operations, including a recent sales agreement allowing for the issuance of up to $50 million in common stock.

Looking ahead, Tevogen anticipates that it will require substantial additional financing to support its ongoing research and development activities and to fund future clinical trials. The company has access to a loan agreement that allows for monthly draws, and it has received grant commitments totaling $7 million from KRHP to further its development efforts. However, management has indicated that it does not plan to initiate any new clinical trials until additional funding is secured, highlighting the critical need for capital to sustain its operations and growth initiatives.